Pre and Post Treatment Metabolomic Analysis of Leukemia: A Translational Clinical Trial of the Brown Cancer Center

University of Louisville (UOFL)

Status

Withdrawn

Conditions

Leukemia

Study type

Observational

Funder types

Other

Identifiers

NCT02193100

BCC-BMT-13 Leuk Metabolomics

Details and patient eligibility

About

To characterize the metabolism of glucose by the leukemic cells in patients with leukemia before and after initial chemotherapy.

To compare the metabolism of glucose by leukocytes in healthy volunteers and leukemic cells in leukemic patients.

Full description

To characterize glycolytic metabolism in patients as demonstrated in leukemic cells and serum metabolite analysis after C13-glucose administration at strategic time points of treatment.

To detect and measure 13C-labeled metabolic markers which may be present in the serum and urine of leukemic patients.

To characterize glycolytic metabolism in patients as demonstrated in leukemic cells and serum metabolite analysis after C13-glucose administration at strategic time points of treatment.

To detect and measure 13C-labeled metabolic markers which may be present in the serum and urine of leukemic patients.

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for Leukemia Subjects:

Each of the criteria in the following section must be met in order for a patient to be eligible for enrollment.
Only patients with clinically diagnosed or histologically diagnosed leukemia will be eligible to participate in this non-therapeutic study.
All patients must have measurable quantities of leukemic blasts on peripheral blood detected with a CBC.
No history of diabetes for the experimental group or the control group.
Patients with known hepatitis C or HIV (AIDS) are excluded.
Patients must be informed of the investigational nature of this study and sign and give written informed consent in accordance with institutional and federal guidelines.

Inclusion Criteria forHealthy Subjects:

Subjects must have no known prior history of cancer or malignant blood disorders. -Where possible, follow up will be carried out to verify that no cancer has developed since the blood collection. This will be done by a phone call performed one month from sample to ask if new medical conditions have arisen.
Subjects must have WBC, RBC, and platelet counts within normal range on CBC.
Subjects with known hepatitis C or HIV (AIDS) are excluded.
No history of Diabetes
At least 30 years of age
Preferably be fasting for 12 hours (minimum 8 hours) prior to enrollment
Patients must be informed of the investigational nature of this study and sign and give written informed consent in accordance with institutional and federal guidelines.

Exclusion Criteria: